NAVI BIO-THERAPEUTICS. INC.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
1. Cancer Gene Testing: NAVI BIO-THERAPEUTICS. INC. provides cancer-related gene screening, enabling individuals to understand or assess the likelihood of cancer development at an early stage. Cancer gene screening, methylated cancer gene testing.
2. KIR Gene Analysis: NAVI BIO-THERAPEUTICS. INC. provides KIR gene analysis services, which can be utilized for cell matching in cell transplantation therapy or for basic research.
3. Immune Cell Culture: NAVI BIO-THERAPEUTICS. INC. provides high-quality technical services for the in vitro culture of various human immune cells, offering clinical-trial-grade cells for research purposes. Natural killer cells, dendritic cells, T cells, immune cell differentiation.
4. Immune Function Testing: NAVI BIO-THERAPEUTICS. INC. provides immune system function analysis services, helping individuals understand their own immune system function at an early stage and assess the likelihood of developing infections or immune-related diseases. Cytokine secretion analysis, immune cell tumor-killing capability testing, dendritic cell subpopulation analysis, lymphocyte population analysis, macrophage phagocytic function, immune cell subpopulation maturity and function analysis.
(The content above was translated by AI.)
2. KIR Gene Analysis: NAVI BIO-THERAPEUTICS. INC. provides KIR gene analysis services, which can be utilized for cell matching in cell transplantation therapy or for basic research.
3. Immune Cell Culture: NAVI BIO-THERAPEUTICS. INC. provides high-quality technical services for the in vitro culture of various human immune cells, offering clinical-trial-grade cells for research purposes. Natural killer cells, dendritic cells, T cells, immune cell differentiation.
4. Immune Function Testing: NAVI BIO-THERAPEUTICS. INC. provides immune system function analysis services, helping individuals understand their own immune system function at an early stage and assess the likelihood of developing infections or immune-related diseases. Cytokine secretion analysis, immune cell tumor-killing capability testing, dendritic cell subpopulation analysis, lymphocyte population analysis, macrophage phagocytic function, immune cell subpopulation maturity and function analysis.
(The content above was translated by AI.)
Founded Year
2013
Unified Business No.
54340420
Status
Active
Number of Employees
0
Total Paid-in
Capital
223,280,000 (NT$)
Location of Company
Taiwan
, Kaohsiung City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
NAVI BIO-THERAPEUTICS. INC. was established in July 2013, developing cell-based immunotherapy technologies, and developing clinical-grade immune cell in vitro culture technologies, clinical immune function analysis technologies, as well as cell culture and separation related equipment. It researches and develops personalized immune cell therapies targeting the prevention and treatment of diseases such as cancer, autoimmune diseases, allergies, and viral infections.
The R&D center of NAVI BIO-THERAPEUTICS. INC. is located in the Asia New Bay Area of Kaohsiung City, featuring a laboratory that complies with GTP regulations to construct a platform for the clinical application of immune cells. The R&D direction of NAVI BIO-THERAPEUTICS. INC. focuses on regulating and improving individual immune system functions through immune cell therapy. Its current core technologies include personalized multi-immune cell therapy, anti-cancer immunofunction assay, closed cell-separation and culture system, and genetically engineered immune cells therapy technology.
The clinical-grade immune cell separation, culture, and therapy technologies are mainly developed through industry-academia collaboration with the Graduate Institute of Clinical Medicine and the Institute of Applied Mechanics at National Taiwan University to jointly develop related equipment and technologies. NAVI BIO-THERAPEUTICS. INC.'s immune cell therapy for cancer focuses on preventing the recurrence of cancer cells, serving as an adjuvant therapy in coordination with existing chemotherapy, radiotherapy, and surgery. The industry-academia collaboration project with National Taiwan University, "Clinical Application of Immune Cell Therapy," will further conduct clinical trials to verify the feasibility of immune cell therapy as an adjuvant medical treatment for cancer.
(The content above was translated by AI.)
The R&D center of NAVI BIO-THERAPEUTICS. INC. is located in the Asia New Bay Area of Kaohsiung City, featuring a laboratory that complies with GTP regulations to construct a platform for the clinical application of immune cells. The R&D direction of NAVI BIO-THERAPEUTICS. INC. focuses on regulating and improving individual immune system functions through immune cell therapy. Its current core technologies include personalized multi-immune cell therapy, anti-cancer immunofunction assay, closed cell-separation and culture system, and genetically engineered immune cells therapy technology.
The clinical-grade immune cell separation, culture, and therapy technologies are mainly developed through industry-academia collaboration with the Graduate Institute of Clinical Medicine and the Institute of Applied Mechanics at National Taiwan University to jointly develop related equipment and technologies. NAVI BIO-THERAPEUTICS. INC.'s immune cell therapy for cancer focuses on preventing the recurrence of cancer cells, serving as an adjuvant therapy in coordination with existing chemotherapy, radiotherapy, and surgery. The industry-academia collaboration project with National Taiwan University, "Clinical Application of Immune Cell Therapy," will further conduct clinical trials to verify the feasibility of immune cell therapy as an adjuvant medical treatment for cancer.
(The content above was translated by AI.)
